Shu-lin Liu

Professor

Nankai University

Short Biography

Dr. Shu-lin Liu a professor and doctoral supervisor at the College of Chemistry, Nankai University, and a recipient of a national-level young scholar program in China. She obtained her bachelor's degree from Zhengzhou University, her doctorate from Wuhan University, and completed her postdoctoral training at the University of Illinois at Chicago. Her research focuses on the development of protein degradation technologies, integrating single-virus tracking, in vivo imaging, and virus-mimicking nanosystems to advance targeted protein degradation strategies for antiviral and cancer therapies. She has published over 90 research papers in peer-reviewed journals, including Nat. Commun., JACS, Angew. Chem., Adv. Mater., Nat. Chem. Biol. and Mol. Cell, with more than 40 papers as first or corresponding author. She has led several national research projects, including the National Key R&D Program and National Natural Science Foundation projects, and her work has provided innovative solutions for the therapeutic application of protein degradation technologies.

Presentation Topic: Programmable and Multiplex Targeted Protein Degradation: From Single Proteins to Dynamic Pathogenic Networks

• Nucleic acid-guided molecular recognition technology overcomes the limitations of traditional druggable targets, enabling precise, sequence-based targeted degradation of pathogenic protein complexes.

• Targeted protein degradation has expanded from the regulation of individual proteins to programmable, system-level therapies, establishing a higher genetic barrier to overcome viral mutation escape and drug resistance.

• An RNA-guided PROTAC platform constructed using conserved viral RNA elements enables the simultaneous degradation of influenza virus ribonucleoprotein complexes (vRNPs), thereby blocking the viral replication process.

• The integration of programmable degraders with nanodelivery systems significantly enhances drug stability in vivo, lung-targeted accumulation, and overall therapeutic efficacy.

• The expansion of nucleic acid-targeted degradation technology to dynamic pathogenic networks provides programmable and scalable new strategies for antiviral, anti-inflammatory, and complex disease treatments.